Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders

• US 7,157,418 B1
• Filed: 07/22/1999
• Issued: 01/02/2007
• Est. Priority Date: 07/22/1998
• Status: Expired due to Fees

• Current Assignee: Osprey Pharmaceuticals USA, Inc. (Osprey Pharmaceuticals Limited)
• Original Assignee: Osprey Pharmaceuticals Limited
• Inventors: Coggins, Philip J., McDonald, John R.
• Primary Examiner(s): Landsman; Robert S.
• Application Number:
  US09/360,242
• Time in Patent Office: 2,721 Days
• Field of Search: 530/300, 530/350, 530/351, 530/402, 424/851, 514/2
• US Class Current: 514/2.4
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 47/62 the modifying agent being a protein, peptide or polyamino acid
• CPC Class Codes: A61K 47/642 the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
• CPC Class Codes: A61K 47/6425 the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
• CPC Class Codes: A61K 47/6811 the drug being a protein or peptide, e.g. transferrin or bleomycin
• CPC Class Codes: C07H 21/04 with deoxyribosyl as saccharide radical
• CPC Class Codes: C07K 14/415 from plants
• CPC Class Codes: C07K 14/521 Chemokines
• CPC Class Codes: C07K 2318/20 Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C07K 2319/01 containing a localisation/targetting motif
• CPC Class Codes: C07K 2319/55 containing a fusion with a toxin, e.g. diphteria toxin
• CPC Class Codes: C07K 7/06 having 5 to 11 amino acids

Abstract

Conjugates containing as a ligand a chemokine receptor targeting agents, such as chemokines, and a targeted agent, such as a toxin are provided. These conjugates are used to treat inflammatory responses associated with activation, proliferation and migration of immune effector cells, including leukocyte cell types, neutrophiles, macrophages, and eosinophils. The conjugates provided herein are used to lessen or inhibit these processes to prevent or at least lessen the resulting secondary effects. In particular, the conjugates are used to target toxins to receptors on secondary tissue damage-promoting cells. The ligand moiety can be selected to deliver the cell toxin to such secondary tissue damage-promoting cells as mononuclear phagocytes, leukocytes, natural killer cells, dendritic cells, and T and B lymphocytes, thereby suppressing the proliferation, migration, or physiological activity of such cells. Among preferred conjugates are fusion proteins having a chemokine, or a biologically active fragment thereof, as the ligand moiety linked to a cell toxin via a peptide linker of from 2 to about 60 amino acid residues.

Claims

1. A method for inhibiting proliferation or migration of activated immune effector cells, comprising administering a conjugate to an animal, whereby proliferation or migration of the immune effector cells is inhibited, wherein:

the conjugate comprises a targeted agent or a portion thereof and a chemokine receptor targeting agent or a portion thereof sufficient to bind to a chemokine receptor on immune effector cells and facilitate internalization of the conjugate;

the chemokine receptor targeting agent is a chemokine, an antibody that specifically binds to a chemokine receptor or a fragment of the chemokine or antibody, wherein the chemokine, antibody or fragment thereof binds to the receptor and internalizes the targeted agent in a cell;

the targeted agent or portion thereof, when internalized in a cell, alters metabolism or gene expression in the cell, regulates or alters protein synthesis in the cell, inhibits proliferation of the cell or kills the cell; and

the conjugate binds to a chemokine receptor resulting in internalization of the targeted agent in cells bearing the receptor.

2. The method of claim 1, wherein the immune effector cells are leukocytes that express chemokine receptors.

3. The method of claim 1, wherein the inflammatory response results in secondary tissue damage.

4. The method of claim 1, wherein the immune effector cells are selected from mononuclear phagocytes (MNP), leukocytes, natural killer cells, dendritic cells, T lymphocytes and B lymphocytes.

5. The method of claims 1, wherein the activated, proliferating or migrating immune cells occur in a disorder or disease state that is selected from the group consisting of CNS injury, CNS inflammatory diseases, neurodegenerative disorders, heart disease, inflammatory eye diseases, inflammatory bowel diseases, inflammatory joint diseases, inflammatory kidney or renal diseases, inflammatory lung diseases, inflammatory nasal diseases, inflammatory thyroid diseases, inflammatory responses associated with bacterial or viral infections and cytokine-regulated cancers.

6. The method of claim 5, wherein the CNS inflammatory diseases and neurodegenerative disorders are selected from the group consisting of stroke, closed head injury, leukoencephalopathy, choriomeningitis, meningitis, adrenoleukodystrophy, AIDS dementia complex, Alzheimer'"'"'s disease, Down'"'"'s Syndrome, chronic fatigue syndrome, encephalitis, encephalomyelitis, spongiform encephalopathies, multiple sclerosis, Parkison'"'"'s disease, and spinal cord injury/trauma (SCI).

7. The method of claim 1, wherein the targeted agent is a toxin.

8. The method of claim 3, wherein the secondary tissue damage results from spinal cord injury or trauma.

10. The method of claim 1, wherein the conjugate is selected from the group consisting of OPL98104, OPL98112, OPL98108, OPL98102, OPL98110, OPL98106, OPL98101, OPL98109, OPL98105, OPL98103, OPL98111 and OPL98107.

11. The method of claim 1, wherein the conjugate comprises the following components:

(chemokine receptor targeting agent)n, (L)q and (targeted agent)m, wherein;

L is a linker for linking the chemokine receptor targeting agent to a targeted agent;

chemokine receptor targeting agent is any moiety that selectively binds to a chemokine receptor and effects internalization of the conjugate;

m and n, which are selected independently, are at least 1; and

q is 0 or more as long as the resulting conjugate binds to the targeted receptor, is internalized and delivers the targeted agent;

the resulting conjugate binds to a receptor that interacts with and internalizes a chemokine, whereby the targeted agent(s) is internalized in a cell bearing the receptor; and

when the conjugate contains a plurality of targeted agents, the targeted agents are the same or different, and when the conjugate contains a plurality of chemokine receptor targeting agents, the targeting agents are the same or different.

12. The method of claim 11, wherein m and n, which are selected independently, are 1–

6.

13. The method of claim 11, wherein q is 1, n is 2 and m is 1.

14. The method of claim 11, wherein the chemokine receptor targeting agent specifically binds to chemokine receptors on activated leukocytes.

15. The method of claim 11, wherein the chemokine receptor targeting agent specifically binds to chemokine receptors on activated cells selected from mononuclear phagocytes (MNP), leukocytes, natural killer cells, dendritic cells, T lymphocytes and B lymphocytes.

16. The method of claim 15, wherein the activated leukocytes are selected from basophils, neutrophils, eosinophils or combinations of any two or more thereof.

17. The method of claim 11, wherein the targeted agent is a toxin, a nucleic acid or a therapeutic protein.

18. The method of claim 11, when the chemokine receptor targeting agent and targeted agent are linked directly via a covalent or ionic linkage.

19. The method of claim 11, wherein the chemokine receptor targeting agent and targeted agent are joined via a linker.

20. The method of claim 19, wherein the linker is a peptide linkage, a polypeptide or is chemical linker.

21. The method of claim 11, wherein the chemokine receptor targeting agent is a chemokine or a fragment thereof that binds to the receptor and internalizes the targeted agent.

22. The method of claim 1, wherein the chemokine receptor targeting agent is a chemokine or a sufficient portion thereof to specifically bind to a chemokine receptor and to facilitate internalization of the conjugate.

23. The method of claim 1, wherein the chemokine targeting agent is a chemokine that is a member of the superfamily of chemokines that interact with at least one of the chemokine receptors selected from the group consisting of the CC-, CXC-, CX3C- and XC-receptors.

24. The method of claim 1, wherein the chemokine targeting agent is a chemokine that is a member of the superfamily of chemokines that interact with at least one of the chemokine receptors selected from the group consisting of the CC- and CXC-receptors.

25. The method of claim 22, wherein the chemokine is selected from the group consisting of IL-8, GCP-2, GRO-α

, GRO-β

, GRP-γ

, ENA-78, PBP, CTAP III, NAP-2, LAPF-4, MIG, IP-10, SDF-1α

, SDF-1β

, SDF-2, MCP-1, MCP-2, MCP-3, MCP4, MCP-5, MIP-1α

, MIP-1β

, MIP-1γ

, MIP-2, MIP-2α

, MIP-3α

, MIP-3β

, MIP-4, MIP-5, MDC, HCC-1, LD78μ

, eotaxin-1, eotaxin-2, I-309, SCYA17, TARC, RANTES, DC-CK-1, lymphotactin and fractalkine.

26. The method of claim 22, wherein the chemokine is selected from the group consisting of lungkine, ALP, Tim-1, chemokine α

-5, chemokine α

-6 and chemokine β

15.

27. The method of claim 1, wherein the chemokine receptor selected from the group-consisting of CXCR-1, CXCR-2, CXCR-3, CXCR4, CXCR-5, CCR-1, CCR-2A, CCR-2B, CCR-3, CCR4, CCR-5, CCR4, CCR-7, CCR-8, CCR-8, CX3CR-1, XCR1, Duffy antigen receptor for chemokines (DARC) and CD97.

28. The method of claim 22, wherein the chemokine receptor is selected from the group consisting of DARC, CXCR-1, CXCR-2, CXCR-3, CXCR4, CCR-1, CCR-2A, CCR-2B, CCR-3, CCR4, CCR-5, CCR6, CCR-7, CCR-8, CX3CR-1, and CD97.

42. The method of claim 1, wherein the targeted agent is selected from among ribosome inactivating proteins (RIPs) and bacteriocins.

44. The method of claim 1, wherein the targeted agent is a toxin that is a ribosome inactivating protein or a toxic subunit thereof.

47. The method of claim 1, wherein the chemokine receptor targeting agent is selected from the group consisting of IL-8, GRO-α

, GRO-β

, IP-10, SDF-1β

, MCP-1 MCP-3, eotaxin-1, eotaxin-2 and RANTES.

48. The method of claim 21, wherein the chemokine receptor targeting agent is selected from the group consisting of IL-8, GCP-2, GRO-α

, GRO-β

, GRP-γ

, ENA-78, PBP, CTAP III, NAP-2, LAPF-4, MIG, IP-10, SDF-1α

, SDF-1β

, SDF-2, MCP-1, MCP-2, MCP-3, MCP4, MCP-5, MIP-1α

, MIP-1β

, MIP-1γ

, MIP-2, MIP-2α

, MIP-3α

, MIP-3β

, MIP-4, MIP-5, MDC, HCC-1, LD-78β

, eotaxin-1, eotaxin-2, I-309, SCYA17, TARC, RANTES, DC-CK-1, lymphotactin, and fractalkine.

51. The method of claim 1, wherein the immune effector cells are selected from among monocytes, macrophages, leukocytes and microglia.

52. The method of claim 11, wherein the immune effector cells are selected from among monocytes, macrophages, leukocytes and microglia.

9. A method for inhibiting the proliferation, migration or activity of secondary tissue damage-promoting inflammatory cells, comprising administering to a subject in need thereof an effective amount of a therapeutic agent that inhibits the proliferation, migration or physiological activity of secondary tissue damage-promoting inflammatory cells, wherein the therapeutic agent is a conjugate that comprises a chemokine receptor targeting agent and a targeted agent or portion thereof selected so that conjugate binds to a chemokine receptor and internalizes the targeted agent, which inhibits the proliferation, migration or physiological activity of the secondary tissue damage-promoting cells.

41. The method of claim 9, wherein the targeted agent, when internalized in a cell, alters metabolism or gene expression in the cell, regulates or alters protein synthesis in the cell, inhibits proliferation of the cell or kills the cell.

49. The method of claim 9, wherein the chemokine receptor targeting agent is selected from the group consisting of IL-8, GCP-2, GRO-α

, GRO-β

, GRP-γ

, ENA-78, PBP, CTAP III, NAP-2, LAPF-4, MIG, IP-10, SDF-1α

, SDF-1β

, SDF-2, MCP-1, MCP-2, MCP-3, MCP-4, MCP-5, MIP-1α

, MIP-1β

, MIP-1γ

, MIP-2, MIP-2α

, MIP-3α

, MIP-3β

, MIP-4, MIP-5, MDC, HCC-1, LD78β

, eotaxin-1, eotaxin-2, I-309, SCYA17, TARC, RANTES, DC-CK-1, lymphotactin, and fractalkine.

29. A method of targeted delivery of an agent into cells that express chemokine receptors, comprising associating the agent with a chemokine receptor targeting agent, whereby:

the chemokine receptor targeting agent binds to a chemokine receptor expressed on the cells; and

the agent is internalized by the cells, wherein the cells are immune effector cells.

30. The method of claim 29, wherein the immune effector cells are activated leukocytes.

40. The method of claim 29, wherein the chemokine is selected from the group consisting of IL-8, GCP-2, GRO-α

, GRO-β

, GRP-γ

, ENA-78, PBP, CTAP III, NAP-2, LAPF-4, MIG, IP-10, SDF-1α

, SDF-1β

, SDF-2, MCP-1, MCP-2, MCP-3, MCP4, MCP-5, MIP-1α

, MIP-1β

, MIP-1γ

, MIP-2, MIP-2α

, MIP-3α

, MIP-3β

, MIP-4, MIP-5, MDC, HCC-1, LD78μ

, eotaxin-1, eotaxin-2, I-309, SCYA17, TARC, RANTES, DC-CK-1, lymphotactin, and fractalkine.

53. The method of claim 29, wherein the immune effector cells are selected from mononuclear phagocytes (MNP), leukocytes, natural killer cells, dendritic cells, T lymphocytes and B lymphocytes.

54. The method of claim 29, wherein the immune effector cells are selected from among monocytes, macrophages, leukocytes and microglia.

55. The method of claim 29, further comprising:

contacting the immune cells with the conjugate or plurality thereof, whereby the toxin is internalized.

56. The method of claim 55, wherein a plurality of conjugates that bind to a plurality of chemokine receptors are prepared, and the immune cells are contacted with each of the conjugates simultaneously or sequentially.

31. A method for inhibiting proliferation or migration of activated immune effector cells, comprising contacting immune effector cells with a conjugate that comprises a targeted agent or a portion thereof and a chemokine receptor targeting agent, whereby activation or proliferation of the immune effector cells is inhibited, wherein:

the targeted agent or portion thereof is a toxin;

the chemokine receptor targeting agent is a chemokine or a fragment of thereof that binds to a chemokine receptor and internalizes the targeted agent; and

the conjugate binds to a chemokine receptor resulting in internalization of the targeted agent in cells bearing the receptor.

32. The method of claim 31, wherein the conjugate comprises the following components:

(chemokine receptor targeting agent)n, (L)q and (targeted agent)m, wherein;

L is a linker for linking the chemokine or fragment thereof to a targeted agent;

m and n, which are selected independently, are at least 1; and

q is 0 or more as long as the resulting conjugate binds to the targeted receptor, is internalized and delivers the targeted agent;

the resulting conjugate binds to a receptor that interacts with and internalizes a chemokine, whereby the targeted agent(s) is internalized in a cell bearing the receptor, and

when the conjugate contains a plurality of targeted agents, the targeted agents are the same or different, and when the conjugate contains a plurality of chemokine receptor targeting agents, the targeting agents are the same or different.

33. The method of claim 32, wherein m and n, which are selected independently, are 1–

6.

34. The method of claim 32, wherein q is 1, n is 2 and m is 1.

35. The method of claim 32, wherein the chemokine specifically binds to chemokine receptors on activated leukocytes.

36. The method of claim 32, wherein the chemokine specifically binds to chemokine receptors on activated cells selected from mononuclear phagocytes (MNP), leukocytes, natural killer cells, dendritic cells, T lymphocytes and B lymphocytes.

37. The method of claim 35, wherein the activated leukocytes are selected from basophils, neutrophils, eosinophils or combinations of any two or more thereof.

38. The method of claim 32, wherein the chemokine is a member of the superfamily of chemokines that interact with at least one of the chemokine receptors selected from the group consisting of the CC-, CXC-, CX3C- and XC-receptors.

39. The method of claim 32, wherein the chemokine is a chemokine that is a member of the superfamily of chemokines that interact with at least one of the chemokine receptors selected from the group consisting of the CC- and CXC-receptors.

43. The method of claim 32, wherein the toxin is a ribosome inactivating protein or a toxic subunit thereof.

45. A method of preparing a candidate compound for treating a disease or disorder involving activated immune cells an inflammatory response, comprising:

identifying immune cells that are activated in the disease or disorder;

identifying chemokine receptors expressed on the cells;

preparing a conjugate or plurality thereof containing toxin linked to a chemokine or a plurality of chemokines that specifically bind to the identified chemokine receptors and effect or facilitate internalization of the toxin into the cells.

46. The method of claim 45, wherein a plurality of conjugates that bind to a plurality of chemokine receptors are prepared.

50. The method of claim 45, wherein the chemokine is selected from the group consisting of IL-8, GCP-2, GRO-α

, GRO-β

, GRP-γ

, ENA-78, PBP, CTAP III, NAP-2, LAPF-4, MIG, IP-10, SDF-1α

, SDF-1β

, SDF-2, MCP-1, MCP-2, MCP-3, MCP4, MCP-5, MIP-1α

, MIP-1β

, MIP-1γ

, MIP-2, MP-2α

, MIP-3α

, MIP-3β

, MIP-4, MIP-5, MDC, HCC-1, LD78β

, eotaxin-1, eotaxin-2, I-309, SCYA17, TARC, RANTES, DC-CK-1, lymphotactin, and fractalkine.